Press Releases Archive

JUN 29, 2009
TearLab Corporation Announces Change in Company Leadership
NOV 11, 2008
Positive Data From the TearLab(TM) Osmolarity System 510K Submission Presented Today at the American Academy of Ophthalmology (AAO) and European Society of Ophthalmology (SOE) 2008 Joint Meeting
NOV 10, 2008
OccuLogix Reports Q3-08 Financial Results
OCT 30, 2008
OccuLogix Regains Compliance With NASDAQ Continued Listing Requirements
OCT 29, 2008
OccuLogix Submits 510(k) Premarket Notification for the Tearlab(TM) Osmolarity System
OCT 15, 2008
OccuLogix Provides Progress Update on the Commercial Development of Its TearLab(TM) Osmolarity System
OCT 7, 2008
OccuLogix Effects Reverse Stock Split
OCT 6, 2008
OccuLogix Announces Closing of Transactions
SEP 30, 2008
OccuLogix Announces Stockholder Approval of Proposals
SEP 16, 2008
OccuLogix Announces Stay of NASDAQ Panel Decision
SEP 8, 2008
OccuLogix Announces Receipt of NASDAQ Panel Decision
AUG 29, 2008
OccuLogix Announces Date of Annual and Special Meeting of Stockholders
AUG 6, 2008
OccuLogix Reports Q2-08 Financial Results
JUL 29, 2008
OccuLogix's Request to Transfer to NASDAQ Capital Market Approved
JUL 28, 2008
OccuLogix Secures Additional Bridge Loan
JUL 21, 2008
OccuLogix, Inc. Files Restatements of Financial Statements
JUN 18, 2008
OccuLogix, Inc. Announces Restatements of Financial Statements Relating to Consolidation of OcuSense, Inc.
MAY 20, 2008
OccuLogix Announces U.S.$5,076,500 Private Placement of Common Stock
MAY 7, 2008
OccuLogix Reports Q1-08 Financial Results
MAY 5, 2008
OccuLogix Secures Additional Bridge Loan
APR 22, 2008
OccuLogix Enters Into Definitive Merger Agreement to Acquire 100% of OcuSense
APR 8, 2008
OccuLogix' POC Diagnostics Subsidiary, OcuSense, Achieves ISO 13485:2003 Certification
APR 4, 2008
OccuLogix' POC Diagnostics Subsidiary Achieves Final TearLab(TM) Osmolarity System Development Milestone and Progresses to Manufacturing Stage
MAR 24, 2008
OccuLogix Receives Going Concern Qualification
MAR 20, 2008
OccuLogix Receives Nasdaq Delisting Letter and Confirms Intention to Appeal
MAR 17, 2008
OccuLogix Reports 2007 Financial Results
FEB 19, 2008
OccuLogix Secures $3 Million Bridge Loan
FEB 5, 2008
OccuLogix Receives Letter From Nasdaq Regarding Non-Compliance With Minimum Market Value of Publicly Held Shares Rule
JAN 9, 2008
OccuLogix Provides Update
DEC 20, 2007
OccuLogix Sells SOLX Subsidiary
NOV 9, 2007
OccuLogix Reports Q3-07 Financial Results
NOV 7, 2007
OccuLogix Provides Update on Expected Timing of Q3-07 Results Release
NOV 1, 2007
OccuLogix Suspends RHEO(TM) System Clinical Development Program
OCT 25, 2007
OccuLogix to Release Q3-07 Financial Results on November 7-Conference Call to Follow
OCT 9, 2007
OccuLogix Board Authorizes Exploration of Strategic Alternatives to Enhance Shareholder Value
SEP 19, 2007
OccuLogix Receives Letter from Nasdaq Regarding Noncompliance with Minimum Bid Price Rule
AUG 8, 2007
OccuLogix Reports Q2-07 Financial Results
JUL 25, 2007
OccuLogix to Release Q2-07 Financial Results on August 8-Conference Call to Follow
JUL 3, 2007
OccuLogix Enters Into Discussions for Private Placement of Common Stock to Private Equity Group
MAY 9, 2007
OccuLogix Reports Q1-07 Financial Results
APR 25, 2007
OccuLogix to Release Q1-07 Financial Results on May 9-Conference Call to Follow
MAR 15, 2007
OccuLogix Receives Going Concern Qualification
MAR 6, 2007
OccuLogix Reports Fourth Quarter and Full-Year 2006 Financial Results
FEB 27, 2007
OccuLogix to Present at Cowen and Company 27th Annual Health Care Conference
FEB 20, 2007
OccuLogix to Announce Fourth Quarter and Full-Year 2006 Financial Results on March 6-Conference Call to Follow
FEB 1, 2007
OccuLogix Announces US$10 Million Private Placement of Common Stock to Institutional Investors
JAN 29, 2007
OccuLogix's RHEO-AMD Trial Protocol Cleared by the FDA
NOV 30, 2006
OccuLogix Further Expands Focus on Age-Related Eye Diseases Through its Equity Investment in OcuSense
NOV 1, 2006
OccuLogix Reports Q3-06 Financial Results
OCT 24, 2006
OccuLogix to Present at CIBC World Markets 17th Annual Healthcare Conference
OCT 23, 2006
OccuLogix and Asahi Kasei Medical Sign Rheofilter'TM' SR Agreement
OCT 17, 2006
OccuLogix to Release Q3-06 Financial Results on November 1-Conference Call to Follow
SEP 1, 2006
OccuLogix Completes Acquisition of SOLX
SEP 1, 2006
OccuLogix Announces Stock Ticker Symbol Changes
AUG 3, 2006
OccuLogix Reports Q2-06 Financial Results
AUG 1, 2006
OccuLogix Enters Into Definitive Agreement to Acquire SOLX
JUL 24, 2006
OccuLogix to Release Q2-06 Financial Results on August 3-Conference Call to Follow
JUN 30, 2006
OccuLogix Terminates Negotiations with Sowood
JUN 14, 2006
OccuLogix Enters Into Letter of Intent for Proposed Private Sale of Zero-Coupon Convertible Notes
JUN 12, 2006
OccuLogix Reports On Meeting With FDA
MAY 8, 2006
OccuLogix Reports Q1-06 Financial Results
MAY 1, 2006
OccuLogix to Release Q1-06 Financial Results on May 8-Conference Call to Follow
APR 4, 2006
OccuLogix Expands Focus on Age-Related Eye Diseases
MAR 9, 2006
OccuLogix Reports Positive MIRA-1 Analysis Results
MAR 9, 2006
OccuLogix Reports Fourth Quarter and Full-Year 2005 Financial Results
MAR 1, 2006
OccuLogix to Release Fourth Quarter & Full Year 2005 Financial Results and Provide a MIRA-1 Analysis Update on March 9-Conference Call to Follow
FEB 3, 2006
OccuLogix Provides MIRA-1 Update
DEC 14, 2005
OccuLogix Announces Acceleration of Stock Options Vesting
DEC 13, 2005
OccuLogix Establishes Scientific Advisory Board
NOV 17, 2005
All 12-Month Follow-up Visits Completed in OccuLogix's Pivotal Trial for Dry Age-Related Macular Degeneration
NOV 9, 2005
OccuLogix Achieves ISO 13485:2003 Certification
NOV 7, 2005
OccuLogix Reports Q3-05 Financial Results
NOV 4, 2005
Time Change Notice-OccuLogix Presentation at SG Cowen 6th Annual Global Healthcare Conference
OCT 20, 2005
OccuLogix Announces Upcoming Investment Community Events
OCT 14, 2005
OccuLogix, Inc.: Options Grant to Steve Parks, Vice President, Sales
OCT 11, 2005
FDA and OccuLogix Agree on Statistical Analysis & Filing Plans
OCT 5, 2005
OccuLogix, Inc.: Accomplished Industry Veteran, Steve Parks, Joins OccuLogix as Vice President of Sales
AUG 30, 2005
OccuLogix to Present at ThinkEquity Partners 3rd Annual Growth Conference
AUG 4, 2005
OccuLogix Reports Q2-05 Financial Results
JUL 21, 2005
OccuLogix to Release Q2-05 Financial Results on August 4-Conference Call to Follow
JUL 18, 2005
OccuLogix, Inc.: Positive PERC Data Presented at ASRS 2005 Annual Meeting
JUN 7, 2005
OccuLogix, Inc.: RHEO'TM' Mechanism of Action Article Published in the Canadian Journal of Ophthalmology
MAY 19, 2005
OccuLogix Appoints Veteran Life Sciences Financial Executive, John Y. Caloz, as CFO
MAY 5, 2005
OccuLogix Reports Q1-05 Financial Results
MAY 3, 2005
OccuLogix, Inc.: Positive RheoNet Registry Clinical Data Presented at ARVO 2005
MAY 2, 2005
OccuLogix Appoints Adrienne L. Graves, Ph.D. to Its Board of Directors
APR 21, 2005
OccuLogix to Release Q1-05 Financial Results on May 5-Conference Call to Follow
APR 18, 2005
OccuLogix Appoints Gilbert S. Omenn, M.D., Ph.D. to Its Board of Directors
APR 12, 2005
OccuLogix to Present at the Scotia Capital Pharmaceutical & Biotechnology Conference
APR 1, 2005
Time Change Notice-OccuLogix Presentation at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
MAR 29, 2005
OccuLogix Re-Acquires its Intellectual Property Rights to Non-Ophthalmic Indications for RHEO in North America
MAR 28, 2005
OccuLogix to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
MAR 11, 2005
OccuLogix to Present at Smith Barney Citigroup 2005 Healthcare Conference
MAR 7, 2005
OccuLogix Reports Fourth Quarter and Year End 2004 Financial Results
MAR 1, 2005
OccuLogix to Present at SG Cowen & Co. 25th Annual Health Care Conference
FEB 28, 2005
OccuLogix Receives FDA Clearance to Initiate MIRA-1 Crossover Studies
FEB 22, 2005
OccuLogix to Release Q4 and Full-year 2004 Financial Results on March 7, 2005-Conference Call to Follow
FEB 3, 2005
OccuLogix to Present at Smith Barney Citigroup 2005 Small & Mid-Cap Conference
JAN 3, 2005
OccuLogix's Pivotal Trial for Dry Age-Related Macular Degeneration Exceeds Patient Recruitment Goal
DEC 16, 2004
OccuLogix, Inc. Closes its Initial Public Offering of 8,400,000 Shares of Common Stock
DEC 9, 2004
OccuLogix, Inc. Prices Initial Public Offering of its Common Stock at US$12 Per Share
AUG 31, 2004
TLC Vision Corporation: Occulogix, Inc. Files Preliminary Prospectus in Canada in Connection With The Initial Public Offering of its Common Stock
AUG 13, 2004
OccuLogix, Inc. Files Registration Statement With The U.S. Securities And Exchange Commission For The Initial Public Offering Of Common Stock
AUG 9, 2004
TLC Vision Corporation And OccuLogix, Inc. Announce OccuLogix, Inc.'s Proposed Initial Public Offering Of Its Common Stock
Powered by InnovasiumGo to Innovasium
Get FlashIt is advised that you have the Macromedia flash plug in for optimal viewing experience.